The University of California Irvine granted Repligen an exclusive license to a U.S. patent application covering the use of HDAC3 inhibitors to treat memory disorders

University of California Irvine

U.S. / Academic

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Repligen Corp.

U.S. / Tools, Services, and Manufacturing

$147.8m on 01/21/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced